Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | STK17B | O94768 | 1/20 | 0.44 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31251145 | 1.00 | CA12 (0.46) | CA12CA1CA2CA9STK17B | |
| SCHEMBL21294560 | 0.82 | BCHE (0.36) | BCHELIPESCN9A | |
| SCHEMBL21294488 | 0.81 | CA12 (0.43) | CA12CA1CA2CA9STK17B | |
| SCHEMBL31250642 | 0.81 | CA12 (0.43) | CA12CA1CA2CA9STK17B | |
| SCHEMBL28604827 | 0.79 | TRPA1 (0.46) | CA12CA1CA2CA9SCN9A | |
| SCHEMBL18862943 | 0.79 | TRPA1 (0.46) | CA12CA1CA2CA9SCN9A | |
| SCHEMBL6991027 | 0.78 | STK17B (0.40) | CA12CA1CA2CA9STK17B | |
| SCHEMBL16593050 | 0.78 | STK17B (0.46) | CA12CA1CA2CA9STK17B | |
| SCHEMBL22425809 | 0.76 | CA12 (0.52) | CA12CA1CA2CA9STK17B | |
| SCHEMBL13648190 | 0.76 | CA12 (0.46) | CA12CA1CA2CA9STK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689366-B2 | Compounds for MALT1 degredation | CORNELL UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689366-B2 | Compounds for MALT1 degredation | CORNELL UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190263785-A1 | COMPOUNDS FOR MALT1 DEGRADATION | CORNELL UNIVERSITY (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263785-A1 | COMPOUNDS FOR MALT1 DEGRADATION | CORNELL UNIVERSITY (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689366-B2 | Compounds for MALT1 degredation | CRBN, NFKB2, NFKB1 | CA12 3546/4885CA1 2550/4885CA2 3924/4885 |
| US-20190263785-A1 | COMPOUNDS FOR MALT1 DEGRADATION | CRBN, NFKB2, NFKB1 | CA12 3654/4885CA1 2693/4885CA2 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.